Asset Details
Do you wish to reserve the book?
Simultaneous administration of mifepristone and misoprostol for early termination of pregnancy: a randomized controlled trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Simultaneous administration of mifepristone and misoprostol for early termination of pregnancy: a randomized controlled trial
Do you wish to request the book?
Simultaneous administration of mifepristone and misoprostol for early termination of pregnancy: a randomized controlled trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Simultaneous administration of mifepristone and misoprostol for early termination of pregnancy: a randomized controlled trial
2011
Overview
Aim
To compare the efficacy of different intervals of misoprostol administration (simultaneously vis-à-vis 24 h), after mifepristone, in women undergoing medical termination of pregnancy up to gestation of 49 days.
Methods
Eighty eligible women with single intrauterine pregnancy of ≤7 weeks of gestation requesting abortion were randomized to receive either 200 mg of mifepristone orally and 400 μg of misoprostol vaginally simultaneously (Group 1) or at 24-h interval (Group 2).Women who had no bleeding after the drugs were offered a second dose of misoprostol 24 h after the first dose. All patients were followed up on day 14. Primary outcome measure was the complete abortion rate. Secondary outcome measures were the induction–abortion interval, adverse effects, especially bleeding, and treatment acceptability rate. Treatment was considered a failure if surgical intervention was needed for any indication.
Results
Complete abortion was achieved in 38 women [95%; 95% confidence interval (CI) 88%, 100%] in Group 1 and 39 women (97.50%; 95% CI 93%,100%) in Group 2 (
p
= 0.56). A second dose of misoprostol was needed in two patients in Group 1 and in only one patient in Group 2. The induction–abortion interval was 6.50 ± 1.48 h in Group 1 and 5.95 ± 1.81 h in Group 2 (
p
= 0.13). The difference in frequency of adverse effects in the two groups was statistically insignificant (
p
= 0.18). The treatment acceptability rate was 97.50% in Group 1 and 95% in Group 2 (
p
= 0.56).
Conclusion
Simultaneous administration of mifepristone and 400 μg vaginal misoprostol is an effective alternative to standard regimens for medical abortion up to 49 days of gestation.
Publisher
Springer-Verlag,Springer Nature B.V
Subject
Abortifacient Agents, Nonsteroidal - administration & dosage
/ Abortifacient Agents, Nonsteroidal - adverse effects
/ Abortifacient Agents, Steroidal - administration & dosage
/ Abortifacient Agents, Steroidal - adverse effects
/ Abortion
/ Administration, Intravaginal
/ Adult
/ Drug Administration Schedule
/ Female
/ Humans
/ Medicine
/ Mifepristone - administration & dosage
/ Mifepristone - adverse effects
/ Misoprostol - administration & dosage
/ Misoprostol - adverse effects
